Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation
Start Date
5/1/2026
Completion Date
12/27/2027
Summary
The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.
Detailed Description
This study is designed to evaluate the effects of GGC supplementation in patients with a history of repetitive head impacts (RHI) who are at risk for developing Traumatic Encephalopathy Syndrome (TES). The trial will include specific individuals who satisfy the eligibility criteria.
Eligibility Criteria
Age Range: 30 years to 70 years
Interventions
Gamma-glutamylcysteine (GGC)
Conditions
Locations
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania 15213
United States